Selective tumor sensitization to taxanes with the mab-drug conjugate cBR96-doxorubicin

International Journal of Cancer

Volumn 93, Issue 4, 2001, Pages 590-600

  Wahl, Alan F ^a   Donaldson, Karen L ^a   Mixan, Bruce J ^a   Trail, Pamela A ^b   Siegall, Clay B ^a  

^a SEATTLE GENETICS INC   (United States)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Antibody mediated; Antitumor targeting; Doxorubicin; Immunoconjugate; Paclitaxel

Indexed keywords

DOXORUBICIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CBR96; PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD GROUP LEWIS SYSTEM; CELL CYCLE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL CYCLE; COLONIC NEOPLASMS; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; IMMUNOTOXINS; INHIBITORY CONCENTRATION 50; LEWIS BLOOD-GROUP SYSTEM; LUNG NEOPLASMS; MICE; MICE, NUDE; PACLITAXEL; TAXOIDS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035882569     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1364     Document Type: Article

References (39)

1. Immuno-conjugates and immunotoxins for therapy of solid tumors
2. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies
3. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens
4. Barriers to drug delivery in solid tumors
5. Oncotic pressure in solid tumors is elevated
6. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications
7. Y-related cell surface antigen
8. Y specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes
9. An unmodified anticarcinoma antibody, BR96, localizes and inhibits the outgrowth of human tumors in nude mice
10. Chimerization of antitumor antibodies via homologous recombination conversion vectors
11. (6-Maleimidocaproyl) hydrazone of doxorubicin - A new derivative for the preparation of immunocojugates of doxorubicin
12. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates
13. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats
14. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors
15. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer
16. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models
17. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines
18. Cytotoxicity of the anticancer agents cisplatin and Taxol during cell proliferaton and the cell cycle
19. Application of a new approach for the quantitation of drug synergism to the combinaton of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine
20. Synthesis and antitumor activity of the immunoconjugate BR96-Dox
21. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts
22. Activation of p34cdc2 coincident with Taxol-induced apoptosis
23. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
24. 2/M arrest and apoptosis
25. Taxol inhibits endosomal-lysosomal membrane trafficking at two distinct steps in CV-1 cells
26. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
27. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
28. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
29. Paclitaxel/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience
30. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts
31. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
32. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis
33. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity
34. Regression of established tumors expressing P-glycoprotein by combinations of Adriamycin, cyclosporin derivaties, and MRK-16 antibodies
35. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
36. Extrapolation of animal toxicity to humans; interspecies comparisons in drug development
37. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin
38. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
39. Separation by counterflow centrifugal elutriation and analysis of T- and B-lymphocytic cell lines in progressive stages of cell division cycle